Cape Town - 2026 ISMRM-ISMRT Annual Meeting and Exhibition
9 May 2026 – 14 May 2026 · Cape Town, South Africa
460-03-010 ISMRM Abstract

Evaluating DCE-MRI and Circulating Tumour DNA for Early Prediction of Neoadjuvant Chemotherapy Response in Breast Cancer

Primary: Analysis Methods - Classification and Prediction
Secondary: Analysis Methods - Radiomics
460-03-010 · Image Classification for Breast Cancer · Tuesday, 12 May, 1:40 PM–2:35 PM · Digital Posters Row A
Keywords: Radiomics Dynamic Contrast-Enhanced MRI Chemotherapy Response Prediction Circulating tumor DNA (ctDNA)
Accepted
Yuet Ying Ko1, Xinzhi Teng1, Tian Li1
1Department of Health Technology and Informatics, The Hong Kong Polytechnic University, Hong Kong, Hong Kong
Presenting Author: Xiang Wang

Synopsis

Motivation:
Goals:
Approach:
Results:
Full abstract & presentation

The full text, figures, and any recorded presentation for this abstract are not shown here. Log in if you are a member or registered attendee with access.

Full abstracts, figures, and presentations for Cape Town - 2026 ISMRM-ISMRT Annual Meeting and Exhibition are available to registered attendees. This content becomes freely available to the public roughly two years after the meeting.

To request or purchase access, contact the ISMRM Central Office at info@ismrm.org.

Log in

References

1. Magbanua MJM, Li W, van 't Veer LJ. Integrating Imaging and Circulating Tumor DNA Features for Predicting Patient Outcomes. Cancers (Basel). 2024;16(10). https://doi.org/10.3390/cancers16101879 [doi]
2. Liang X, Yu X, Gao T. Machine learning with magnetic resonance imaging for prediction of response to neoadjuvant chemotherapy in breast cancer: A systematic review and meta-analysis. Eur J Radiol. 2022;150:110247. https://doi.org/10.1016/j.ejrad.2022.110247 [doi]
3. Granzier RWY, van Nijnatten TJA, Woodruff HC, Smidt ML, Lobbes MBI. Exploring breast cancer response prediction to neoadjuvant systemic therapy using MRI-based radiomics: A systematic review. Eur J Radiol. 2019;121:108736. https://doi.org/10.1016/j.ejrad.2019.108736 [doi]
4. Li W, Newitt DC, Gibbs J, Wilmes LJ, Jones EF, Arasu VA, et al. Predicting breast cancer response to neoadjuvant treatment using multi-feature MRI: results from the I-SPY 2 TRIAL. NPJ Breast Cancer. 2020;6(1):63. https://doi.org/10.1038/s41523-020-00203-7 [doi]
5. Papakonstantinou A, Gonzalez NS, Pimentel I, Sunol A, Zamora E, Ortiz C, et al. Prognostic value of ctDNA detection in patients with early breast cancer undergoing neoadjuvant therapy: A systematic review and meta-analysis. Cancer Treat Rev. 2022;104:102362. https://doi.org/10.1016/j.ctrv.2022.102362 [doi]
6. Panet F, Papakonstantinou A, Borrell M, Vivancos J, Vivancos A, Oliveira M. Use of ctDNA in early breast cancer: analytical validity and clinical potential. npj Breast Cancer. 2024;10(1):50. https://doi.org/10.1038/s41523-024-00653-3 [doi]
7. Magbanua MJM, Li W, Wolf DM, Yau C, Hirst GL, Swigart LB, et al. Circulating tumor DNA and magnetic resonance imaging to predict neoadjuvant chemotherapy response and recurrence risk. NPJ Breast Cancer. 2021;7(1):32. https://doi.org/10.1038/s41523-021-00239-3 [doi]
8. Zwanenburg A, Leger S, Agolli L, Pilz K, Troost EGC, Richter C, et al. Assessing robustness of radiomic features by image perturbation. Sci Rep. 2019;9(1):614. https://doi.org/10.1038/s41598-018-36938-4 [doi]

Cite this abstract

http://echo.ismrm.org/p/ISMRM2026/460-03-010